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Purpose: To compare outcomes in visual acuity, refractive error, higher-order aberrations 
(HOAs), contrast sensitivity, and dry eye in patients undergoing laser in situ keratomileusis 
(LASIK) using wavefront (WF) guided VISX CustomVue and WF optimized WaveLight 
Allegretto platforms.
Methods: In this randomized, prospective, single-masked, fellow eye study, LASIK was per-
formed on 44 eyes (22 patients), with one eye randomized to WaveLight Allegretto, and the 
fellow eye receiving VISX CustomVue. Postoperative outcome measures at 3 months included 
uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), refrac-
tive error, root-mean-square (RMS) value of total and grouped HOAs, contrast sensitivity, and 
Schirmers testing.
Results: Mean values for UDVA (logMAR) were −0.067 ± 0.087 and −0.073 ± 0.092 in the 
WF optimized and WF guided groups, respectively (P = 0.909). UDVA of 20/20 or better was 
achieved in 91% of eyes undergoing LASIK with both lasers while UDVA of 20/15 or bet-
ter was achieved in 64% of eyes using the Allegretto platform, and 59% of eyes using VISX 
  CustomVue (P = 1.000). In the WF optimized group, total HOA increased 4% (P = 0.012), 
coma increased 11% (P = 0.065), and spherical aberration increased 19% (P = 0.214), while 
trefoil decreased 5% (P = 0.490). In the WF guided group, total HOA RMS decreased 9% 
(P = 0.126), coma decreased 18% (P = 0.144), spherical aberration decreased 27% (P = 0.713) 
and trefoil decreased 19% (P = 0.660). One patient lost one line of CDVA secondary to residual 
irregular astigmatism.
Conclusion: Both the WaveLight Allegretto and the VISX CustomVue platforms had equal 
visual and safety outcomes. Most wavefront optimized HOA values trended upward, with a 
statistically significant increase in total HOA RMS. Eyes treated with the WF guided platform 
showed a decreasing trend in HOA values.
Keywords: wavefront guided, wavefront optimized, laser in situ keratomileusis, LASIK, 
Allegretto, VISX
Introduction
Conventional laser refractive surgery platforms are capable of correcting lower-order 
aberrations, such as hyperopia, myopia, and astigmatism. Higher-order aberrations 
(HOAs), such as coma, spherical aberration, and trefoil, are induced by, and remain 
uncorrected in, traditional laser in situ keratomileusis (LASIK) surgery.1,2Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Although conventional LASIK surgery is mostly accurate, 
abundant research has shown reoperation rates for primary 
myopic keratorefractive surgery are between 5.5% and 
19.2%.3–9 When HOAs cannot be corrected, image quality 
may suffer.1,2,10–13 The HOAs call for more advanced optical 
measurements and more sophisticated laser algorithms. These 
laser algorithms are found in wavefront (WF) based treat-
ments, which have been shown to diminish induced HOAs 
compared to traditional LASIK, and increase predictability 
of visual outcomes.14–18 As WF based methods have evolved 
rapidly over the years, an important question is whether there 
are significant differences in the induced HOAs and visual 
outcomes between specific WF guided and WF optimized 
platforms used in LASIK.
To date, multiple studies have compared WF guided 
and WF optimized platforms in LASIK surgery.19–24 The 
data shows varied results, with some studies suggesting an 
advantage to WF guided platforms,19,22–24 and others showing 
no significant difference between the two platforms.20,21 In this 
prospective, randomized, fellow eye study, we compared WF 
guided VISX CustomVue platform (Abbott Medical Optics 
[AMO], Santa Ana, CA) with WF optimized WaveLight 
Allegretto platform (Alcon, Inc, Hüenberg, Switzerland) in the 
same patient undergoing LASIK, with respect to visual acuity, 
refractive error, HOAs, contrast sensitivity, and dry eyes.
Patients and methods
This prospective, single masked, randomized, fellow eye 
study evaluated and compared the outcomes of LASIK per-
formed on 44 eyes (22 patients) using the VISX CustomVue 
laser system and the WaveLight Allegretto laser system. 
Patients were recruited and enrolled at the John A Moran Eye 
Center, Department of Ophthalmology and Visual Science, 
University of Utah, between December 2010 and July 2011. 
All patients were over the age of 21.
The University of Utah Hospital Institutional Review Board 
approved the research protocol in accordance with the tenets 
of the Declaration of Helsinki. All patients provided informed 
consent after they received an explanation of the procedure, 
including all risks and benefits. All patients had a preoperative 
discussion of relevant medical history, including history of 
herpetic eye disease and family history of keratoconus.
Patients were excluded if they had a history of clinically 
significant lens opacity, previous corneal or intraocular sur-
gery, thin corneas, keratoconus, unstable refraction, amblyo-
pia, or autoimmune disease; were pregnant or breastfeeding; 
or were on immunosuppressive therapy. Patients desiring 
monovision were not included in the study.
Eligible patients were scheduled for bilateral LASIK and 
correction for distance in both eyes. The patients were ran-
domly assigned (Research Randomizer software –   Urbaniak, 
www.randomizer.org) to treatment in one eye with the 
WaveLight Allegretto system (WF optimized group), which 
utilizes the WaveLight® Allegretto 400 Hz Wave® Eye-Q 
Laser. The fellow eye was assigned treatment with the VISX 
CustomVue™ STAR S4 IR™ Excimer Laser with Active-
Track™ iris registration (WF guided group). The patients 
were blinded as to which laser was used for treatment in 
each eye. No patient had LASIK enhancement at any time 
during the study.
Soft contact lenses were discontinued 2 weeks before 
screening and rigid gas permeable contact lenses were 
discontinued 6 weeks before screening. All patients had 
a preoperative examination including manifest refraction 
(MRX) and cycloplegic refraction, uncorrected distance 
visual acuity (UDVA), corrected distance visual acuity 
(CDVA),   tonometry, slitlamp examination, and dilated 
fundus evaluation. Corneal topography and thickness 
were measured using the Pentacam (OCULUS Optikgeräte 
GmbH, Wetzlar, Germany) and Humphrey Atlas (Carl 
Zeiss   Meditec, Inc, Jena, Germany) systems. Pupil size 
was measured in the dark using the Colvard pupillometer 
(Oasis Medical, Inc, Glendora, CA). Contrast sensitivity 
was performed using the VectorVision CSV-1000 (Day-
ton, OH) chart in controlled mesopic (70 lux) conditions 
at three, six, twelve, and 18 cycles per degree. Schirmers 
testing evaluation for dry eye was measured in millimeters 
with topical anesthetic after 5 minutes. MRX and WF mea-
surements were repeated on two separate visits to ensure 
refractive stability.
All eyes received five preoperative wavefront analyses 
using the VISX CustomVue WaveScan aberrometer v 3.62 
(Fourier) (AMO), without pharmacologic intervention, 
under mesopic conditions, with a minimum pupil diameter 
of 6.0 mm. The emmetropic correction target was based on 
MRX, topography, and wavefront analysis for the WF guided 
group. For the WF optimized group, emmetropic correction 
target was based on topography and MRX. Iris registra-
tion was obtained for eyes receiving WF guided   treatment. 
  Previously established Moran Laser Center WF guided 
LASIK nomograms were followed for both the Allegretto and 
the CustomVue treatments. The nomograms were generated 
with Datagraph-med refractive outcomes software (v 3.20a; 
Ingenieurbüro Pieger GmbH, Wendelstein, Germany) using 
a minimum of 50 eyes for each wavefront platform with a 
minimum follow-up of 3 months.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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All LASIK flaps were created with an iFS™ Advanced 
Femtosecond Laser (AMO) at 150 kHz in a raster pattern with 
bed energy of 1.15 µJ, side cut energy of 2.00 µJ, and pocket 
enabled. Flaps were created with an intended thickness of 
110 µm, diameter of 8.4 to 9.0 mm, superior hinge angle of 
55°, and a side cut angle of 70°. If the 8.0 mm maximum 
intended ablation diameter exceeded the flap diameter, the 
hinge and flap were shielded during ablation. All surgeries 
were performed by Majid Moshirfar and Mark D Mifflin.
Postoperatively, each eye received one drop of gatifloxa-
cin 0.3% (Allergan Inc, Irvine, CA) and prednisolone acetate 
1% (Allergan, Inc). The prednisolone acetate was continued 
hourly on postoperative day 1, and then four times daily for 
6 additional days. The gatifloxacin was continued four times 
daily for 1 week.
Patients were seen and data was collected at 1 day, 1 week, 
and 1 and 3 months after surgery. UDVA and CDVA were 
tested using a standard Snellen eye chart. Visual acuity 
was recorded in both Snellen notation and logarithm of the 
minimum angle of resolution (logMAR) format. Evaluation of 
contrast sensitivity, dry eye, and HOAs were performed. HOAs 
including total HOA root mean square (RMS), coma Z(3,1), 
trefoil Z(3,3), and spherical aberration Z(4,0), were measured 
using the WaveScan aberrometer. Undilated scans of both 
eyes were taken at 3 months postoperatively regardless of the 
wavefront platform used for treatment. Subjective outcomes 
were recorded using the Quality of Life Impact of Refractive 
Correction (QIRC) instrument. The ratings from the QIRC 
were interpreted using the guidelines set by Pesudovs et al.25
Statistics
After the study was completed, the results were compiled and 
the data unmasked for statistical analysis. MRX, refractive error, 
visual acuity, contrast sensitivity, HOA values for coma, trefoil, 
and sphere, and HOA RMS wavefront aberration values were 
treated as continuous variables and analyzed for significance 
by using a paired Student’s t-test. A P value of 0.05 or less was 
considered statistically significant. Data analysis was performed 
using Microsoft Excel (Microsoft Corp, Redmond, WA).
Results
22 patients (44 eyes) with 3 months of postoperative care 
were evaluated in this study. The sample population con-
sisted of 15 women and seven men with a mean age of 31.2 
years ± 6.3 standard deviation (SD) (range 23 to 53 years). 
Baseline data showed no significant differences in preopera-
tive CDVA or refractive error (Table 1).
Visual acuity
UDVA and CDVA were not statistically different between 
the groups at 1 or 3 months (Table 2). Postoperatively, 20/15 
UDVA was achieved in 64% and 59% of the eyes in the WF 
optimized and WF guided groups, respectively. Three months 
after surgery, 91% of the eyes in both groups achieved 20/20 
UDVA (Table 3). Postoperatively, spherical equivalent and 
sphere measurements decreased significantly in the WF 
optimized group compared to the WF guided group at 1 and 
3 months (P = 0.020, P = 0.017). There was no significant 
difference in cylinder measurements in either group before 
or after surgery.
Safety, efficacy, and predictability
At 1 month, 21 eyes (95%) in the WF optimized group and 
18 (81%) in the WF guided group were within ± 0.50 diopters 
(D) of emmetropia. In addition, ten eyes (45%) in the WF 
optimized group and six eyes (27%) in the WF guided group 
were within ±0.25 D of emmetropia (P = 0.035). Although 
there was a significant difference in emmetropia at 1 month, 
this did not remain significant at 3 months (Table 3).
At 3 months, one eye (5%) in the WF optimized group lost 
one line of CDVA. The vision loss was attributed to residual 
irregular astigmatism confirmed by topography. No other eyes 
Table 1 Preoperative group comparisons
Parameter Platform P-value*
Allegretto (n = 22) VISX (n = 22)
Age 31.7 ± 6.30
Male/female 7/15
Mean LogMAr CDVA −0.03 ± 0.06 (−0.125 to 0) −0.03 ± 0.06 (−0.125 to 0) 1.000
CDVA (20/X) 18.6 ± 2.28 (15 to 20) 18.6 ± 2.28 (15 to 20) 1.000
spherical equivalent (D) −3.61 ± 1.98 (−7.25 to 1.50) −3.86 ± 1.81 (−7.25 to −0.375) 0.137
sphere (D) −3.97 ± 2.10 (−7.75 to 1) −4.17 ± 1.99 (−7.5 to −0.375) 0.191
Cylinder 0.70 ± 0.97 (0 to 4.25) 0.63 ± 0.78 (0 to 2.25) 0.461
Notes: Values represented as mean ± standard deviation (range); *paired student’s t-test.
Abbreviations: UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; logMAr, logarithm of the minimum angle of resolution.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Table 2 One month and three month visual acuity comparisons
Parameter Allegretto (n = 22) VISX (n = 22) P-value*
Postoperative month 1
UDVA (LogMAr) −0.04 ± 0.10 (−0.125 to 0.176) −0.05 ± 0.11 (−0.125 to 0.301) 0.515
UDVA (20/x) 19.3 ± 5.19 (15 to 30) 19.3 ± 7.29 (15 to 40) 1.000
CDVA (LogMAr) −0.05 ± 0.08 (−0.125 to 0.097) −0.06 ± 0.07 (−0.301 to 0.097) 0.745
CDVA (20/x) 18.1 ± 3.35 (15 to 25) 17.6 ± 3.01 (10 to 25) 0.329
spherical equivalent (D) 0.02 ± 0.24 (−0.05 to 0.625) 0.32 ± 0.51 (−0.375 to 1.125) 0.020
sphere (D) −0.08 ± 0.29 (−0.75 to 0.5) 0.25 ± 0.48 (−0.5 to 1.75) 0.012
Cylinder (D) 0.19 ± 0.27 (0 to 0.75) 0.14 ± 0.17 (0 to 0.5) 0.234
Postoperative month 3
UDVA (LogMAr) −0.07 ± 0.09(−0.125 to 0.301) −0.07 ± 0.09 (−0.301 to 0.097) 0.714
UDVA (20/x) 17.5 ± 4.01 (15 to 30) 17.3 ± 3.69 (10 to 25) 0.747
CDVA (LogMAr) −0.11 ± 0.08 (−0.301 to 0.097) −0.10 ± 0.09 (−0.301 to 0) 0.909
CDVA (20/x) 15.9 ± 2.94 (10 to 25) 16.1 ± 3.06 (10 to 20) 0.747
spherical equivalent (D) 0.04 ± 0.27 (−0.375 to 0.75) 0.30 ± 0.43 (−0.25 to 1.75) 0.017
sphere (D) −0.1 ± 0.31 (−0.5 to 0.75) 0.18 ± 0.39 (−0.25 to 1.25) 0.049
Cylinder (D) 0.26 ± 0.28 (0 to 0.75) 0.23 ± 0.28 (0 to 1) 0.623
Notes: Values represented as mean ± standard deviation (range); *paired student’s t-test.
Abbreviations: UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; logMAr, logarithm of the minimum angle of resolution.
Table 3 Efficacy, predictability, and safety comparison of allegretto and VISX laser platforms
Postoperative month 1 Postoperative month 3
Parameter Allegretto (n = 22) VISX (n = 22) P-value* Allegretto (n = 22) VISX (n = 22) P-value*
Efficacy (UDVA) 0.778 1.000
20/15 or better 10 (45%) 12 (55%) 14 (64%) 13 (59%)
20/20 or better 18 (82%) 19 (86%) 20 (91%) 20 (91%)
20/30 or better 22 (100%) 20 (91%) 21 (95%) 22 (100%)
20/40 or better 22 (100%) 22 (100%) 22 (100%) 22 (100%)
20/50 or better 22 (100%) 22 (100%) 22 (100%) 22 (100%)
Predictability 0.035 0.199
±0.25 D of emmetropia 10 (45%) 6 (27%) 17 (77%) 15 (68%)
±0.50 D of emmetropia 21 (95%) 18 (81%) 21 (95%) 18 (82%)
±1.00 D of emmetropia 22 (100%) 20 (91%) 22 (100%) 22 (100%)
Safety (CDVA) 1.000 1.000
Loss of 2 lines or more 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Loss of 1 line 3 (14%) 2 (10%) 1 (5%) 0 (0%)
no loss of lines 13 (62%) 13 (62%) 9 (41%) 12 (55%)
gain of 1 line 5 (24%) 6 (29%) 11 (50%) 9 (41%)
gain of 2 lines or more 0 (0%) 0 (0%) 1 (5%) 1 (5%)
Notes: Values represented as number of eyes (percentege); *paired student’s t-test.
Abbreviations: UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; logMAr, logarirhm of the minimum angle of resolution.
in the study population lost any lines of CDVA. Nine eyes 
(41%) in the WF optimized group maintained equal CDVA 
compared to twelve eyes (55%) in the WF guided group. 
Eleven eyes (50%) in the WF optimized group and nine eyes 
(41%) in the WF guided group gained one line of CDVA. 
One eye in both groups gained two lines (P = 1.000).
schirmers testing
The preoperative average Schirmers test value for the WF 
optimized group was 19.9 mm ± 9.95 and 22.1 mm ± 9.98 
for the WF guided group. At 1 month the values were 
20.3 mm ± 8.52 and 21.1 mm ± 10.2 for the WF optimized 
group and the WF guided group, respectively. The 3 months 
postoperative values were 21.1 mm ± 7.83 for the WF opti-
mized group and 20 mm ± 8.12 for the WF guided group. 
There was no significant difference in Schirmers testing 
between both groups during the study period (P $ 0.081).
Contrast sensitivity
Contrast sensitivity did not change significantly in either 
group when preoperative measurements were compared to 
postoperative measurements (P $ 0.07) (Figure 1).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Figure 1 Comparison of contrast sensitivity between allegretto and VisX laser platforms at 3, 6, 12, and 18 cycles per degree (CPD) preoperatively (n = 22) and at 3 months 
postoperatively (n = 22) using the Vectrovision CsV-1000e chart (P $ 0.066 for all measurements at any time).
higher-order aberrations
At 3 months postoperatively, 15 eyes (68%) in each 
group completed CustomVue WaveScan analysis. The 
only statistically significant change discovered was a 4% 
increase in total HOA RMS (P = 0.012) in the WF opti-
mized group. In this group, other HOAs had nonsignificant 
changes, which showed the following: coma increased 11% 
(P = 0.065), trefoil decreased 5% (P = 0.239) and spherical 
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Figure 2 Comparison of higher-order aberrations before surgery (n = 16) and 3 months postoperatively (n = 16) in the wavefront optimized platform. Total, coma, Z(3, 1), 
trefoil, Z(3, 3), and spherical aberration, Z(4, 0) were measured using the Wavescan at a mean diameter of 6 mm. 
Note: *Statistically significant (P = 0.012).
Abbreviation: rMs hOA, root-mean-square higher order aberration. 
aberration increased 19% (P = 0.214) (Figure 2). The WF 
guided group showed a decreasing trend in HOA values, 
with total HOA RMS, coma, trefoil, and spherical aber-
ration decreasing 9% (P = 0.126), 18% (P = 0.144), 19% 
(P = 0.660), and 28% (P = 0.713) respectively (Figure 3). 
There were no significant differences in preoperative or 
postoperative HOA values between the WF guided or WF 
optimized groups.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Figure 3 Comparison of higher-order aberrations before surgery (n = 16) and 3 months postoperatively (n = 16) in the wavefront-guided platform. Total, coma, Z(3, 1), 
trefoil, Z(3,3), and spherical aberration, Z(4, 0) were measured using the Wavescan at a mean diameter of 6 mm (P $ 0.126).
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Figure 4 Preoperative (n = 20) and 3 months postoperative (n = 20) comparison of 
mean Quality of Life impact of refractive Correction (QirC) questionnaire scores 
(P , 0.001).
Quality of life
Mean QIRC values were obtained preoperatively and at 
3 months postoperatively. Postoperative mean QIRC val-
ues at 3 months were 27% higher than preoperative values 
(P , 0.001) (Figure 4).
Complications
No intraoperative complications occurred in the study popu-
lation. One eye lost one line of CDVA in the WF optimized 
group. The patient had 4.00 D of astigmatism preoperatively, 
and the loss of vision was determined to be due to residual 
astigmatism with some irregularity confirmed by topography. 
No other eyes in the sample population lost any lines of 
CDVA. Complications included three eyes with nonvisually 
significant microstriae, one of which was slightly overcor-
rected. All patients with microstriae were in the −7.00 D 
range preoperatively. The overcorrected eye was in the WF 
guided group, and had a terminal spherical equivalent mea-
suring +1.75 D. This patient remains at 20/20 UDVA. No 
other complications were observed.
Discussion
In a recent retrospective study comparing VISX Custom-
Vue to WaveLight Allegretto platforms in LASIK sur-
gery,   Perez-Straziota et al found there were no significant 
  differences in visual outcomes or induced HOAs.20 To the best 
of our knowledge, we report the first prospective, randomized, 
single masked, fellow eye study between these lasers.
Our study supports previous comparative research 
that the VISX CustomVue WF guided platform and the 
WaveLight Allegretto WF optimized platform are effec-
tive and predictable in LASIK surgery.19–23,26 We found a Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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statistically significant difference in postoperative sphere 
and spherical equivalent in the WF optimized group. 
Additionally, a greater percentage of the WF optimized 
eyes fell within ±0.50 D of emmetropia at 1 month, but at 
3 months both groups were equal. Cylinder values did not 
differ significantly between the wavefront platforms. There 
were no statistically significant differences in outcomes of 
UDVA, CDVA, contrast sensitivity, or Schirmers testing at 
3 months postoperatively.
Comparisons of various WF guided and WF optimized 
platforms in LASIK have not shown a consistent advantage 
in reduction of HOAs in either platform.19,21–24 In comparing 
two WF guided platforms, Alcon CustomCornea and VISX 
CustomVue, Moshirfar et al observed that both platforms 
led to a small increase in total HOAs.26 Several authors have 
compared similar Allegretto WF guided and Allegretto WF 
optimized lasers prospectively.19,21,23 Padmanabhan et al con-
cluded there was no significant difference between the two 
modalities in terms of visual acuity or refractive outcomes, 
although WF guided technology induced significantly fewer 
HOAs.19 Miraftab et al saw no significant difference of 
induced HOAs between either group.21 Lastly, Stonecipher 
and Kezirian observed that WF guided treatment was more 
beneficial for patients with a high degree of preoperative 
HOA RMS.23 Brint,22 followed by Tran and Shah,24 compared 
Alcon CustomCornea WF guided treatment to Allegretto WF 
optimized treatment. Both found a statistically significant 
increase in HOAs using the Allegretto platform in compari-
son to WF guided platform.22,24
We observed a similar pattern of results for HOAs after 
LASIK. We found a significant increase in mean total HOA 
RMS in the WF optimized group, along with a nonsignifi-
cant trend of decrease in trefoil, and increase in coma and 
spherical aberration. Conversely, the WF guided group 
showed a nonsignificant decreasing trend in HOA values 
postoperatively. Similarly, Miraftab et al found postoperative 
nonstatistically significant increasing trends in total HOA, 
C7 vertical coma, and spherical aberration, with a decreas-
ing trend in trefoil for their WF optimized platform.21 Also, 
Randleman et al showed a nonsignificant trend of increases 
in total HOA, coma, trefoil, and spherical aberration in their 
WF optimized LASIK study.18
In regards to patient satisfaction with WF guided vs WF 
optimized LASIK, Yu et al showed no significant difference 
in objective measurements on the QIRC questionnaire.27 We 
observed significant increases postoperatively in quality of 
life measures in our study population. We were unable to 
compare VISX CustomVue to WaveLight Allegretto using 
the QIRC because this survey instrument does not separate 
subjective results based on each eye. We administered an 
additional subjective survey, but the data received was 
limited and no conclusions could be drawn. While short 
subjective surveys after LASIK have allowed for conclu-
sions in previous literature,28 we believe our ten item survey 
instrument would benefit from a larger sample size.
Our study showed one eye that lost one line of CDVA 
in the WF optimized group, which was caused by a persis-
tent irregular astigmatism, in absence of a flap complica-
tion. This postoperative outcome has been observed by 
Levinson et al in their study on complications leading to 
cornea specialist referral after LASIK.29 One patient in our 
study experienced overcorrection in the WF guided group. 
Efforts to prevent overcorrection were attempted by com-
paring preoperative WaveScan refractions to manifest and 
cycloplegic refractions. The overcorrection did not impact 
this patient’s postoperative UDVA, which was 20/20 with 
no subjective complaints. We attribute this UDVA in the 
setting of overcorrection to the patient’s accommodation. 
This patient had a high degree of preoperative myopia with 
a high spherical equivalent, which has been correlated with 
LASIK overcorrection.30
Limitations of the study include small sample size and 
short-term follow-up. We hope to continue to follow our 
study patients to better assess long-term outcomes. A pos-
sible limitation in comparing the VISX WF guided platform 
to the Allegretto WF optimized platform is that the VISX 
CustomVue WaveScan aberrometer is specifically designed 
for the VISX STAR S4 platform. One may argue that the 
aberrometer (WaveLight® Analyzer, Alcon, Inc, Hüenberg, 
Switzerland) made for use with Allegretto may have shown 
different results. However, authors have used a single aber-
rometer platform to compare various wavefront lasers with 
consistent results.20,22
Because the statistically significant differences between 
the platforms were small, we feel both WF optimized 
and WF guided platforms can provide safe and effective 
outcomes in LASIK. In our experience, the challenges 
associated with WF guided techniques included pupil size 
requirements, mismatch to MRX which was mostly due to 
over accommodation, and the timely process of uploading 
wavefront data. The Allegretto WaveLight Eye-Q laser 
functions at a higher frequency, therefore allowing faster 
operating times. Additionally, the Allegretto platform 
does not require iris registration, which can sometimes be Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
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  difficult to obtain intraoperatively, and there is no issue with 
mismatch to MRX.
In conclusion, no significant differences were observed 
in regards to UDVA, CDVA, dry eye, or contrast sensi-
tivity when comparing the WaveLight Allegretto Wave 
Eye-Q laser to the VISX CustomVue STAR S4 IR Exci-
mer Laser with ActiveTrack iris registration. While the 
WF optimized platform showed superior outcomes for 
refractive measures of sphere and spherical equivalent, 
postoperative visual acuity was not statistically differ-
ent between the study groups. Most WF optimized HOA 
values tended to increase, with a statistically significant 
increase in total HOA RMS. In contrast, there was a trend 
for WF guided HOA values to decrease, although not with 
statistical significance.
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